PAREXEL Receives CEO Cancer Gold Standard Re-Accreditation
July 11 2017 - 9:00AM
Business Wire
Recognized for commitment to employee health
and well-being by CEO Roundtable on Cancer
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced that
the CEO Roundtable on Cancer has again named PAREXEL a CEO Cancer
Gold Standard™ employer. The biennial U.S.-based accreditation,
which PAREXEL previously received in 2015, recognizes the Company’s
strong commitment to the health of its employees and their
families.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170711005056/en/
The Gold Standard provides a framework for employers to have
healthier workplaces by focusing on cancer risk education, early
detection, access to clinical trials and high-quality care. To earn
the accreditation, companies must demonstrate concrete efforts to
address cancer in the workplace. PAREXEL has several programs in
place to help its employees reduce cancer risk, including:
- Promoting physical activity, healthy
nutrition and weight management
- Offering a medical incentive program to
reduce an employee’s health plan contribution costs following
completion of health and wellness activities
- Providing health insurance options that
include detection of cancer at its earliest stages, participation
in cancer clinical trials and access to quality care
- Supporting the needs of cancer
survivors in the workplace
- Prohibiting tobacco use and supporting
cessation efforts
“At PAREXEL, our employees are the key to our success as we help
our clients bring life-saving treatments to patients around the
globe,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “We
are honored that the CEO Roundtable on Cancer has once again named
us a Gold Standard employer for our continued commitment to the
health and well-being of our employees and their families.”
About the CEO Roundtable on Cancer
The CEO Roundtable on Cancer is a nonprofit
organization of CEOs founded in 2001, when former President George
H.W. Bush challenged a group of executives to "do something bold
and venturesome about cancer within your own corporate families."
The CEOs responded by creating and encouraging the widespread
adoption of the CEO Cancer Gold Standard™, which calls for
organizations to evaluate their health benefits and workplace
culture and take extensive, concrete actions in five key areas of
health and wellness to address cancer in the workplace. For more
information on the CEO Cancer Gold Standard and the
no-cost, web-based accreditation process, please
visit www.CancerGoldStandard.org.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services company, providing a broad range of
expertise-based clinical research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170711005056/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1-781-434-4753Email: ron.aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024